Details of the Drug

General Information of Drug (ID: DMM9ORD)

Drug Name
ASG-15ME
Indication
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Phase 1 [1]
Urothelial carcinoma 2C92.0 Phase 1 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0UM4S
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SLIT and NTRK-like family member 6 (SLITRK6) TTTVEKI SLIK6_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bladder tissue
The Studied Disease Bladder cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
SLIT and NTRK-like family member 6 (SLITRK6) DTT SLITRK6 7.13E-05 -2.93 -3.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01963052) ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Seattle Genetics.